Atea is trying to turn from a cash-burning drug developer into a product company as its hepatitis C pill moves through late-stage testing against today’s go-to treatment. The upside hinges on whether doctors and insurers see enough real-world benefit to switch—and whether a second bet in hepatitis E can open a new market with no approved options.Read more
Atea Pharmaceuticals is nearing make-or-break trial results for its hepatitis C pill, but even good data may not translate into strong sales if insurers push back on pricing and access. The bigger long-term upside hinges on whether its second program can move from early testing into a real option for patients with chronic hepatitis E.Read more
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral direct acting antiviral therapies for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Read more
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
